1338326-83-2

Upstream product

• 106-40-1 4-bromo-aniline 
• 87600-97-3 4,6-dichloropyrimidine-5-carboxylic acid chloride 
• 496856-44-1 methyl 2-(3-chloro-4-(triuoromethylsulfonyloxy)phenyl)acetate 
• 1259022-53-1 methyl 2-(3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate 
• 1338326-84-3 4-amino-6-(4-bromophenyl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338326-85-4 6-(4-bromophenyl)-4-chloro-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338326-86-5 N-(4-bromophenyl)-4,6-dichloro-N-(2-hydroxyethyl)pyrimidine-5-carboxamide 
• 1338326-87-6 N-(4-bromophenyl)-N-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4,6-dichloropyrimidine-5-carboxamide 
• 1338326-88-7 4-bromo-N-[2-[tert-butyl(dimethyl)silyl]oxyethyl]aniline 
• 57017-95-5 methyl 3-chloro-4-hydroxyphenylacetate 

Downstream Products

• 1338326-25-2 (R)-4-amino-6-(2'-chloro-4'-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)biphenyl-4-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338326-82-1 2-(4'-(a-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)-2-chlorobiphenyl-4-yl)acetic acid 

Relevant academic research and scientific papers

Discovery and optimization of efficacious neutral 4-amino-6-biphenyl-7,8- dihydropyrimido[5,4-f][1,4]oxazepin-5-one diacylglycerol acyl transferase-1 (DGAT1) inhibitors

A series of neutral DGAT1 inhibitors with good potency and pharmacokinetics (PK) has been designed by modification of an acidic startpoint. This was achieved by selecting the acid with the highest ligand lipophilicity efficiency (LLE) and replacing the ac

4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.